For losers in the $14 billion bidding war over drugmaker Medivation Inc., the best cure for the mergers and acquisitions blues may be to go shopping.
That’s good news for BioMarin Pharmaceutical Inc., Biogen Inc., Incyte Corp., Clovis Oncology Inc. and Tesaro Inc., which were mentioned by analysts Monday as potential targets for drugmakers that lost out to Pfizer. Shares of all four companies rose following the takeover announcement, partly becau...
05:39 Why Trump’s Inaugural May Look a Lot Like Nixon’s22
21:32 This Artist's Dazzling Travel Journals Will Inspire Your Next Trip20
14:53 Netflix fueled by original programming, even as its costs hold earnings back, analysts say17
16:31 What will Jared Kushner and Donald Trump's Middle East look like?16